Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Apr. 03, 2016
Research and Development Expense [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Research and Development Expense [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	3.00%
Operating Segments [Member] | Brands [Member] | Global Innovative Pharmaceutical [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Operating Segments [Member] | Brands [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	71.00%
Operating Segments [Member] | Brands [Member] | Global Established Pharmaceutical [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	29.00%
Operating Segments [Member] | In Process Research and Development [Member] | Global Innovative Pharmaceutical [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	2.00%
Operating Segments [Member] | In Process Research and Development [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	10.00%
Operating Segments [Member] | In Process Research and Development [Member] | Global Established Pharmaceutical [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	85.00%